Eagle Pharmaceuticals, Inc. Share Price

Equities

EGRX

US2697961082

Pharmaceuticals

Real-time Estimate Cboe BZX 12:31:17 18/06/2024 am IST 5-day change 1st Jan Change
4.01 USD +4.16% Intraday chart for Eagle Pharmaceuticals, Inc. +12.78% -23.23%
Sales 2021 172M 14.32B Sales 2022 317M 26.44B Capitalization 380M 31.77B
Net income 2021 -8M -668M Net income 2022 35M 2.92B EV / Sales 2021 3.44 x
Net cash position 2021 67.84M 5.66B Net Debt 2022 10.19M 851M EV / Sales 2022 1.23 x
P/E ratio 2021
-77 x
P/E ratio 2022
10.7 x
Employees 134
Yield 2021 *
-
Yield 2022
-
Free-Float 65.14%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.16%
1 week+12.78%
Current month+15.71%
1 month-15.65%
3 months-28.56%
6 months-15.65%
Current year-23.23%
More quotes
1 week
3.50
Extreme 3.5
4.07
1 month
3.21
Extreme 3.2101
4.78
Current year
3.21
Extreme 3.2101
6.81
1 year
3.21
Extreme 3.2101
23.52
3 years
3.21
Extreme 3.2101
58.25
5 years
3.21
Extreme 3.2101
64.94
10 years
3.21
Extreme 3.2101
104.17
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 01/13/01
Director of Finance/CFO 81 01/07/01
Compliance Officer - 01/21/01
Members of the board TitleAgeSince
Director of Finance/CFO 81 01/07/01
Director/Board Member 55 28/19/28
Director/Board Member 63 17/17/17
More insiders
Date Price Change Volume
18/24/18 4.015 +4.29% 78 452
14/24/14 3.85 +0.79% 127,215
13/24/13 3.82 +4.09% 128,950
12/24/12 3.67 -0.27% 88,522
11/24/11 3.68 +3.37% 92,104

Delayed Quote Nasdaq, June 18, 2024 at 12:21 am IST

More quotes
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.
Related indices
More about the company